tiprankstipranks
Advertisement

JDVI - ETF AI Analysis

Compare

Top Page

JDVI

John Hancock Disciplined Value International Select ETF (JDVI)

Rating:59Neutral
Price Target:
JDVI, the John Hancock Disciplined Value International Select ETF, appears to be a solid but not top-tier fund, supported by several strong core holdings. High-quality companies like Novartis and AstraZeneca, with robust financial performance, positive earnings sentiment, and solid product pipelines, help lift the fund’s overall quality, while other sizable positions such as BAE Systems and Rexel introduce some caution due to weaker technical trends or richer valuations. The main risk factor is the fund’s meaningful exposure to a mix of cyclical and value-oriented international names, where overbought signals and valuation concerns in a few holdings could weigh on future returns.
Positive Factors
Strong Recent Performance
The ETF has shown solid gains so far this year and in the most recent month, indicating positive momentum.
Leading Holdings Performing Well
Several of the largest positions, especially in materials and industrials, have delivered strong returns, helping drive the fund’s overall results.
Broad International Diversification
Holdings spread across multiple countries such as Japan, the UK, France, Switzerland, and others help reduce reliance on any single market.
Negative Factors
Relatively High Expense Ratio
The fund’s fee level is on the higher side for an ETF, which can gradually reduce net returns for long-term investors.
Sector Concentration in Materials and Financials
A large share of assets in materials and financial companies makes the fund more sensitive to downturns in these specific sectors.
Some Underperforming Health Care Exposure
At least one major health care holding has been weak recently, which can act as a drag on the fund’s performance if the trend continues.

JDVI vs. SPDR S&P 500 ETF (SPY)

JDVI Summary

John Hancock Disciplined Value International Select ETF (JDVI) is an actively managed fund that invests in international stocks with a value focus, meaning companies the managers believe are priced lower than they’re worth. It spreads money across many countries, including the U.S., Japan, and the U.K., and across sectors like materials, financials, and health care. Well-known holdings include Novartis and AstraZeneca. Someone might invest in JDVI for long-term growth and diversification outside the U.S. stock market. A key risk is that value stocks and international markets can go in and out of favor, so the price can move up and down significantly.
How much will it cost me?The John Hancock Disciplined Value International Select ETF (JDVI) has an expense ratio of 0.69%, meaning you’ll pay $6.90 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on selecting undervalued international stocks through detailed research and analysis.
What would affect this ETF?JDVI's focus on undervalued international companies could benefit from global economic recovery, especially in sectors like Financials and Industrials, which make up a significant portion of its holdings. However, challenges such as rising interest rates or geopolitical tensions could negatively impact its performance, particularly in regions outside the U.S. Additionally, fluctuations in commodity prices may affect holdings like Kinross Gold and Rio Tinto.

JDVI Top 10 Holdings

JDVI leans heavily on global materials and industrial names, with miners like Kinross Gold, Rio Tinto, and Teck Resources doing much of the heavy lifting as they’ve been rising and giving the fund a clear commodities flavor. Mitsubishi Electric has also been climbing, adding an industrial tailwind, while Nutrien’s more mixed path and BAE Systems’ recent wobble keep returns from looking too smooth. Large European pharma players such as Novartis and Roche provide a steadier, defensive counterweight, rounding out a broadly diversified, ex-U.S. value lineup.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Kinross Gold5.71%$4.71M$39.26B126.29%
81
Outperform
Nutrien4.51%$3.72MC$47.08B32.41%
75
Outperform
Novartis AG4.34%$3.58MCHF207.57B22.86%
80
Outperform
Roche Holding AG4.10%$3.38M$327.62B29.84%
73
Outperform
Mitsubishi Electric3.50%$2.89M¥12.60T102.86%
72
Outperform
Sumitomo Mitsui Financial Group3.24%$2.67M¥20.41T57.39%
77
Outperform
Teck Resources3.20%$2.64M$29.43B69.11%
66
Neutral
AstraZeneca3.12%$2.57M$292.93B34.19%
80
Outperform
Nordea Bank Abp3.02%$2.49Mkr576.35B36.73%
BAE Systems2.96%$2.43M£59.22B26.17%
61
Neutral

JDVI Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
37.42
Positive
100DMA
36.98
Positive
200DMA
34.71
Positive
Market Momentum
MACD
0.24
Positive
RSI
52.93
Neutral
STOCH
38.08
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For JDVI, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 38.15, equal to the 50-day MA of 37.42, and equal to the 200-day MA of 34.71, indicating a neutral trend. The MACD of 0.24 indicates Positive momentum. The RSI at 52.93 is Neutral, neither overbought nor oversold. The STOCH value of 38.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JDVI.

JDVI Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$699.85M0.69%
59
Neutral
$994.63M0.59%
67
Neutral
$496.29M0.55%
71
Outperform
$282.91M0.30%
59
Neutral
$280.60M0.60%
61
Neutral
$106.53M0.45%
66
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JDVI
John Hancock Disciplined Value International Select ETF
38.05
9.58
33.65%
MFSI
MFS Active International ETF
OSEA
Harbor International Compounders ETF
AVDS
Avantis International Small Cap Equity ETF
QLTI
GMO International Quality ETF
IDYN
iShares International Equity Factor Rotation Active ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement